SEC Comment Letter 0000000000-24-000503 to Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: Jan. 16, 2024 · CIK: 0001601936 · Accession: 0000000000-24-000503
AI Filing Summary & Sentiment
File numbers found in text: 333-276427
Letter
United States securities and exchange commission logo January 16, 2024 Thomas Meyer Chief Executive Officer Altamira Therapeutics Ltd. 8 The Green Suite 12455 Dover, DE 19901 Re:Altamira Therapeutics Ltd. Registration Statement on Form F-3 Filed January 8, 2024 File No. 333-276427 Dear Thomas Meyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Lerner
Show Raw Text
United States securities and exchange commission logo
January 16, 2024
Thomas Meyer
Chief Executive Officer
Altamira Therapeutics Ltd.
8 The Green
Suite 12455
Dover, DE 19901
Re:Altamira Therapeutics Ltd.
Registration Statement on Form F-3
Filed January 8, 2024
File No. 333-276427
Dear Thomas Meyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael Lerner